Institution
St. Paul's Hospital
Healthcare•Vancouver, British Columbia, Canada•
About: St. Paul's Hospital is a healthcare organization based out in Vancouver, British Columbia, Canada. It is known for research contribution in the topics: Population & Health care. The organization has 3492 authors who have published 4752 publications receiving 156148 citations.
Papers published on a yearly basis
Papers
More filters
••
Theo Vos1, Amanuel Alemu Abajobir, Kalkidan Hassen Abate2, Cristiana Abbafati3 +775 more•Institutions (305)
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of prevalence, incidence, and years lived with disability (YLDs) for 328 causes in 195 countries and territories from 1990 to 2016.
10,401 citations
••
TL;DR: Both overweight and obesity are associated with the incidence of multiple co-morbidities including type II diabetes, cancer and cardiovascular diseases, and maintenance of a healthy weight could be important in the prevention of the large disease burden in the future.
Abstract: Background
Overweight and obese persons are at risk of a number of medical conditions which can lead to further morbidity and mortality. The primary objective of this study is to provide an estimate of the incidence of each co-morbidity related to obesity and overweight using a meta-analysis.
3,006 citations
••
TL;DR: Reduced lung function is associated with increased levels of systemic inflammatory markers which may have important pathophysiological and therapeutic implications for subjects with stable COPD.
Abstract: Background: Individuals with chronic obstructive pulmonary disease (COPD) are at increased risk of cardiovascular diseases, osteoporosis, and muscle wasting. Systemic inflammation may be involved in the pathogenesis of these disorders. A study was undertaken to determine whether systemic inflammation is present in stable COPD. Methods: A systematic review was conducted of studies which reported on the relationship between COPD, forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC), and levels of various systemic inflammatory markers: C-reactive protein (CRP), fibrinogen, leucocytes, tumour necrosis factor-a (TNF-a), and interleukins 6 and 8. Where possible the results were pooled together to produce a summary estimate using a random or fixed effects model. Results: Fourteen original studies were identified. Overall, the standardised mean difference in the CRP level between COPD and control subjects was 0.53 units (95% confidence interval (CI) 0.34 to 0.72). The standardised mean difference in the fibrinogen level was 0.47 units (95% CI 0.29 to 0.65). Circulating leucocytes were also higher in COPD than in control subjects (standardised mean difference 0.44 units (95% CI 0.20 to 0.67)), as were serum TNF-a levels (standardised mean difference 0.59 units (95% CI 0.29 to 0.89)). Conclusions: Reduced lung function is associated with increased levels of systemic inflammatory markers which may have important pathophysiological and therapeutic implications for subjects with stable COPD.
1,672 citations
••
TL;DR: Low-dose vasopressin did not reduce mortality rates as compared with norepinephrine among patients with septic shock who were being treated with conventional (catecholamine) vasopressesors, and a test for heterogeneity between these two study strata was not significant.
Abstract: Background Vasopressin is commonly used as an adjunct to catecholamines to support blood pressure in refractory septic shock, but its effect on mortality is unknown. We hypothesized that low-dose vasopressin as compared with norepinephrine would decrease mortality among patients with septic shock who were being treated with conventional (catecholamine) vasopressors. Methods In this multicenter, randomized, double-blind trial, we assigned patients who had septic shock and were receiving a minimum of 5 μg of norepinephrine per minute to receive either low-dose vasopressin (0.01 to 0.03 U per minute) or norepinephrine (5 to 15 μg per minute) in addition to open-label vasopressors. All vasopressor infusions were titrated and tapered according to protocols to maintain a target blood pressure. The primary end point was the mortality rate 28 days after the start of infusions. Results A total of 778 patients underwent randomization, were infused with the study drug (396 patients received vasopressin, and 382 norepinephrine), and were included in the analysis. There was no significant difference between the vasopressin and norepinephrine groups in the 28-day mortality rate (35.4% and 39.3%, respectively; P = 0.26) or in 90-day mortality (43.9% and 49.6%, respectively; P = 0.11). There were no significant differences in the overall rates of serious adverse events (10.3% and 10.5%, respectively; P = 1.00). In the prospectively defined stratum of less severe septic shock, the mortality rate was lower in the vasopressin group than in the norepinephrine group at 28 days (26.5% vs. 35.7%, P = 0.05); in the stratum of more severe septic shock, there was no significant difference in 28-day mortality (44.0% and 42.5%, respectively; P = 0.76). A test for heterogeneity between these two study strata was not significant (P = 0.10). Conclusions Low-dose vasopressin did not reduce mortality rates as compared with norepinephrine among patients with septic shock who were treated with catecholamine vasopressors. (Current Controlled Trials number, ISRCTN94845869.)
1,385 citations
••
Scott & White Hospital1, Columbia University Medical Center2, Stanford University3, Cleveland Clinic4, St. Paul's Hospital5, Duke University6, Cedars-Sinai Medical Center7, Lenox Hill Hospital8, University of Pennsylvania9, Emory University10, MedStar Washington Hospital Center11, New York University12, Brigham and Women's Hospital13
TL;DR: The findings show that TAVR as an alternative to surgery for patients with high surgical risk results in similar clinical outcomes.
1,319 citations
Authors
Showing all 3504 results
Name | H-index | Papers | Citations |
---|---|---|---|
Marco A. Marra | 153 | 620 | 184684 |
Daniel S. Berman | 141 | 1363 | 86136 |
Marcello Tonelli | 128 | 701 | 115576 |
David Robertson | 127 | 1106 | 67914 |
James A. Russell | 124 | 1024 | 87929 |
John G. Webb | 123 | 730 | 76025 |
Edwin K. Silverman | 115 | 670 | 43901 |
Nestor L. Müller | 111 | 547 | 45508 |
Julio S. G. Montaner | 105 | 971 | 58944 |
Gordon R. Bernard | 103 | 346 | 70417 |
Edward J Mills | 102 | 497 | 71902 |
James C. Hogg | 102 | 485 | 45147 |
Thomas L. Patterson | 101 | 587 | 36220 |
Eric Lam | 99 | 492 | 34893 |
Robert S. Hogg | 96 | 662 | 43036 |